FDA Brief

Warning letters Food

FDA warning letter to

Bea Lydecker’s Naturals, Inc.

High riskIssued Feb 9, 2022Posted Mar 8, 2022Division of Human and Animal Food Operations West VI

FDA says Bea Lydecker’s Naturals marketed supplements and CBD products as unapproved drugs for diseases.

What happened

FDA inspected Bea Lydecker’s Naturals’ dietary supplement distributing facility in Oregon City, Oregon, on June 6, 11, and 24, 2021, and reviewed labels, catalogs, brochures, newsletters, and the website www.bealydecker.com in February 2022. FDA found claims that many products were intended to cure, treat, mitigate, or prevent diseases including cancer, COVID-19, AIDS, Ebola, heart disease, and arthritis. FDA also found some products misbranded and noted promotion of CBD Oil Procana Spectrum for humans and animals and unapproved new animal drug products.

What FDA found

  1. FDA says claims on labels, catalogs, brochures, newsletters, and the website show the products are intended to cure, treat, mitigate, or prevent disease.

    FD&C Act section 201(g)(1)(B) [21 U.S.C. § 321(g)(1)(B)]
  2. FDA says the products are unapproved new drugs because they are not generally recognized as safe and effective for those uses and lack FDA approval.

    FD&C Act sections 201(p)(1), 301(d), and 505(a) [21 U.S.C. §§ 321(p)(1), 331(d), 355(a)]
  3. FDA says some products lack adequate directions for use because their intended diseases are not amenable to self-diagnosis or treatment.

    FD&C Act section 502(f)(1) [21 U.S.C. § 352(f)(1)]
  4. FDA says several listed products are misbranded under section 403.

    FD&C Act section 403 [21 U.S.C. § 343]
  5. The letter also identifies Equine Calmer, Equine Artho-Flex, and Calmer as unapproved new animal drugs.

What FDA wants

FDA asks the company to correct the violations and respond to the warning letter; the provided excerpt does not give a response deadline.

Who should pay attention

  • dietary supplement makers and retailers
  • companies marketing herbal, CBD, or animal products with disease claims
  • quality teams reviewing labeling and website claims

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk